Organization | University of Brasilia

University of Brasilia Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Brasilia Brazil (1962)

Organization Overview

First Clinical Trial

2006

NCT00317980

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Brasilia Heart Study Group | Brasilia University | Brasilia University - Brasilia's University Hospital - Geriatric Medical Center | Brasilia University - Brasilia's University Hospital - Geriatric Medical Centre | Brasilia University Hospital | Faculty of Medicine, University of Brasilia | FAMEP | Hospital de Base | Hospital de Base do Distrito Federal | Hospital de Base do Distrito Federal, Brazil | Hospital Oftalmologico de Brasilia | Hospital Universitario de Brasilia | Instituto de Cardiologia do Distrito Federal, Brasilia, Brazil | João Luiz Q. Durigan | Universidade de Brasilia | University Hospital of Brasilia | University of BrasÃlia | University of Brasilia | University of Brasília | University of Brasilia Medical School | University of Brasilia Medical School, Brasilia, Brazil

Active Ingredients

Drugs in Phase 4 Trials (24)

amphotericin b (fungizone) (3 trials)

clofazimine (lamprene) (1 trial)

dapsone (aczone) (1 trial)

deoxycholic acid (kybella) (1 trial)

ephedrine (1 trial)

esmolol (brevibloc) (3 trials)

ezetimibe (zetia) (1 trial)

fentanyl (Innovar) (1 trial)

glyburide (micronase) (1 trial)

ketorolac (acuvail) (1 trial)

lidocaine (xylocaine) (6 trials)

magnesium sulfate (Tis-U-Sol) (3 trials)

meglumine (4 trials)

methylglucamine antimoniate (2 trials)

montelukast (singulair) (1 trial)

nepafenac (nevanac) (1 trial)

ondansetron (zofran) (2 trials)

palonosetron (aloxi) (1 trial)

propofol (diprivan) (2 trials)

remifentanil (ultiva) (4 trials)

rifampin (1 trial)

sevoflurane (ultane) (2 trials)

simvastatin (zocor) (4 trials)

vildagliptin (1 trial)

Drugs in Phase 3 Trials (15)

chamomile (3 trials)

dexmedetomidine (precedex) (1 trial)

fibrinogen (human) (RiaSTAP) (1 trial)

human fibrin (Tisseel) (1 trial)

miltefosine (impavido) (3 trials)

minoxidil (loniten) (1 trial)

mirtazapine (remeron) (1 trial)

oxytocin (syntocinon) (1 trial)

pentoxifylline (trental) (2 trials)

rocuronium (zemuron) (1 trial)

sodium chloride (2 trials)

tranilast (1 trial)

trazodone (desyrel) (1 trial)

urea (3 trials)

zoplicone (1 trial)

Drugs in Phase 2 Trials (3)

Amorolfine (loceryl) (1 trial)

ringer's lactate (1 trial)

yinhsing (1 trial)

Drugs in Phase 1 Trials (1)

diazepam (valium) (1 trial)

Drugs in Other Trials (4)

coffee (2 trials)

maltodextrin (2 trials)

orange juice (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alopecia (Phase 3)

Alopecia Areata (Phase 3)

Alzheimer Disease (Phase 3)

Asthma (Phase 4)

Bradycardia (Phase 3)

Cataract (Phase 4)

Cough (Phase 3)

Delirium (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Disease (Phase 3)

Edema (Phase 4)

Emergence Delirium (Phase 3)

Head and Neck Neoplasms (Phase 3)

Hearing Loss (Phase 2)

Hypersensitivity (Phase 4)

Hypertension (Phase 4)

Hypotension (Phase 4)

Infarction (Phase 4)

Inflammation (Phase 4)

Insulin Resistance (Phase 4)

Joint Diseases (Phase 3)

Leishmaniasis (Phase 4)

Leishmaniasis, Cutaneous (Phase 4)

Leishmaniasis, Mucocutaneous (Phase 2)

Leishmaniasis, Visceral (Phase 4)

Leprosy (Phase 4)

Macular Edema (Phase 4)

Myocardial Infarction (Phase 4)

Onychomycosis (Phase 2)

Pain, Postoperative (Phase 4)

Parasomnias (Phase 3)

Psychomotor Agitation (Phase 3)

Pterygium (Phase 3)

Radiodermatitis (Phase 3)

Sleep Initiation and Maintenance Disorders (Phase 3)

Sleep Wake Disorders (Phase 3)

Spondylolisthesis (Phase 3)

Spondylolysis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 52
# of Trial APIs: 47